VAPAWAY.EU - Research and education on VAP prevention
  • Home
  • Articles
  • GuideLines
  • Links
  • About VAPAWAY
  • Training
  • Contacts

Login








Lost Password?

Register to receive updated data on VAPAWAY initiative

Agenda

 

9 - 12 March 2010

ISICEM International Symposium on Intensive Care and Emergency Medicine - Brussels (Belgium)

ISICEM

 

9 -11 June 2010

EACTA European Association of Cardiothoracic Anaesthesiologists - Edinburgh (UK)

EACTA

 

12-15 June 2010

ESA European Society of Anaesthesiology - Helsinki (Finland)

ESA

 

18-22 September 2010

ERS European Respiratory Society - Barcellona (Spain)

ERS

 

9 -13 October 2010

ESICM European Society of Intensive Care Medicine - Barcellona (Spain)

ESICM

  

 

> International events   

> Local events 

INCIDENCE AND RISK FACTORS FOR VAP AFTER MAJOR HEART SURGERY PDF Print E-mail
Monday, 01 February 2010
Hortal J, Giannella M, Pérez MJ, Barrio JM, Desco M, Bouza E, Muñoz P. 
Department of Anesthesia, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Intensive Care Med. 2009 Sep;35(9):1518-25.

PURPOSE: Major heart surgery (MHS) patients are a particularly high-risk population for nosocomial infections. Our objective was to identify risk factors for ventilator-associated pneumonia (VAP) in patients undergoing MHS.

METHODS: Prospective study including 1,844 patients operated from 2003 to 2006. RESULTS: Overall 106 patients (140 episodes) developed one or more episodes of VAP (5.7%, 22.2 episodes per 1,000 days of mechanical ventilation). VAP incidence was 45.9% in those patients requiring more than 48 h of MV. Enterobacteriaceae (32.8), Pseudomonas aeruginosa (28.6%) and Staphylococcus aureus (27.1%, of which 65.8% were methicillin resistant) were the principal microorganisms causing VAP. The independent risk factors for VAP were: age >70, perioperative transfusions, days of mechanical ventilation, reintubation, previous cardiac surgery, emergent surgery and intraoperative inotropic support. Median length of stay in the ICU for patients who developed VAP or not was, respectively, 25.5 versus 3 days (P < 0.001), and mortality was, respectively, 45.7 versus 2.8% in both populations (P < 0.001). We developed a predictive preoperative score with a sensitivity of 93% and a specificity of 40%.

CONCLUSIONS: VAP is common in patients undergoing MHS that require more than 48 h of MV. In that "high-risk" population,

 
Next >
Select and watch
from the following webinars

 


Join us on www.smartonweb.org

Partner

VAPAWAY is proudly supported by Covidien.

http://www.covidien.com